FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: A historical cohort

Journal of Experimental and Clinical Cancer Research

Volumn 32, Issue 1, 2013, Pages

  Maugeri Saccà, Marcello ^a   Pizzuti, Laura ^a   Sergi, Domenico ^a   Barba, Maddalena ^a   Belli, Franca ^b   Fattoruso, Silvia Ileana ^c   Giannarelli, Diana ^a   Amodio, Antonella ^a   Boggia, Sara ^d   Vici, Patrizia ^a   Di Lauro, Luigi ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b Italian Charcot Marie Tooth Association (AICMT) Clinic   (Italy)

^c Division of Oncology Fiorini Hospital   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

FOLFIRI; Gastric cancer; Second line chemotherapy

Indexed keywords

CAPECITABINE; CISPLATIN; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER FATIGUE; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CONTINUOUS INFUSION; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; STOMACH CANCER; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; TAXOIDS;

EID: 84883866029     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-32-67     Document Type: Article

References (30)

1. Global cancer statistics. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D, CA Cancer J Clin 2011 61 69 90 10.3322/caac.20107 21296855
2. Current questions for the treatment of advanced gastric cancer. Cervantes A, Roda D, Tarazona N, Roselló S, Pérez-Fidalgo JA, Cancer Treat Rev 2013 39 60 67 10.1016/j.ctrv.2012.09.007 23102520
3. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Glimelius B, Ekström K, Hoffman K, Graf W, Sjödén PO, Haglund U, Svensson C, Enander LK, Linné T, Sellström H, Heuman R, Ann Oncol 1997 8 163 168 10.1023/A:1008243606668 9426339 (Pubitemid 27112884)
4. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M, Cancer 1993 72 37 41 10.1002/1097-0142(19930701)72:1<37::AID- CNCR2820720109>3.0.CO;2-P 8508427 (Pubitemid 23182046)
5. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Pyrhönen S, Kuitunen T, Nyandoto P, Kouri M, Br J Cancer 1995 71 587 591 10.1038/bjc.1995.114 7533517
6. V325 Study Group. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani JA, J Clin Oncol 2006 24 4991 4997 10.1200/JCO.2006.06.8429 17075117 (Pubitemid 46631401)
7. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H, Takeuchi M, Lancet Oncol 2008 9 215 221 10.1016/S1470-2045(08)70035-4 18282805
8. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK, ToGA Trial Investigators, Lancet 2010 376 687 697 10.1016/S0140-6736(10)61121-X 20728210
9. Capecitabine and oxaliplatin for advanced esofagogastric cancer. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR, Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom, N Eng J Med 2008 358 36 46 10.1056/NEJMoa073149
10. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitgemeinschaft internistische onkologie. Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, Rethwisch V, Seipelt G, Homann N, Wilhelm G, Schuch G, Stoehlmacher J, Derigs HG, Hegewisch-Becker S, Grossmann J, Pauligk C, Atmaca A, Bokemeyer C, Knuth A, Jäger E, J Clin Oncol 2008 26 1435 1442 10.1200/JCO.2007.13.9378 18349393
11. Randomized multicenter phase II trial of a biweekly regimen of fluouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Fédération Francophone de Cáncerologie Digestive Group Study-FFCD 9803. Bouché O, Raoul JL, Bonnetain F, Giovannini M, Etienne PL, Lledo G, Arsène D, Paitel JF, Guérin-Meyer V, Mitry E, Buecher B, Kaminsky MC, Seitz JF, Rougier P, Bedenne L, Milan C, J Clin Oncol 2004 22 4319 4328 10.1200/JCO.2004.01.140 15514373 (Pubitemid 41199650)
12. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer-a randomized phase III study of the Arbeitgemeinschaft Internische Onkologie (AIO). Thuss-Patience P, Kretzschmar A, Bichev D, Deist T, Hinke A, Breithaupt K, Dogan Y, Gebauer B, Schumacher G, Reichardt P, Eur J Cancer 2011 15 2306 2314
13. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. Kang JH, Lee SI, Lim DH, Park KW, Oh SY, Kwon HC, Hwang IG, Lee SC, Nam E, Shin DB, Lee J, Park JO, Park YS, Lim HY, Kang WK, Park SH, J Clin Oncol 2012 30 1513 1518 10.1200/JCO.2011.39.4585 22412140
14. Geographic differences in approach to advanced gastric cancer: Is there a standard approach? Kim R, Tan A, Choi M, El-Rayes BF, Crit Rev Oncol Hematol 2013 doi: 10.1016/j.critrevonc.2013.05.007. [Epub ahead of print]
15. Docetaxel, oxaliplatin, and capecitabine (DOX) combination chemotherapy for metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma [abstract ]. Di Lauro L, Sergi D, Belli F, Fattoruso SI, Arena MG, Pizzuti L, Vici P, J Clin Oncol 2013 31 Suppl 15065
16. Epirubicin, cisplatin and docetaxel combination therapy for metastatic gastric cancer. Di Lauro L, Belli F, Arena MG, Carpano S, Paoletti G, Giannarelli D, Lopez M, Ann Oncol 2005 16 1498 1502 10.1093/annonc/mdi281 15956036 (Pubitemid 41222422)
17. Phase II study of epirubicin, oxaliplatin and docetaxel combination in metastatic gastric or gastroesophageal junction adenocarcinoma. Di Lauro L, Giacinti L, Arena MG, Sergi D, Fattoruso SI, Giannarelli D, Lopez M, J Exp Clin Cancer Res 2009 28 34 10.1186/1756-9966-28-34 19267943
18. Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO). Roth AD, Maibach R, Martinelli G, Fazio N, Aapro MS, Pagani O, Morant R, Borner MM, Herrmann R, Honegger H, Cavalli F, Alberto P, Castiglione M, Goldhirsch A, Ann Oncol 2000 11 301 306 10.1023/A:1008342013224 10811496 (Pubitemid 30214667)
19. Randomized phase III study or irinotecan (CPT-11) versus weekly paclitaxel (wPTX) fir advanced gastric cancer (AGC) refractory to combination chemotherapy (CT) of fluoropyrimidine plus platinum (FP): WJOG4007 [abstract ]. Ueda S, Hironaka S, Yasui H, Nishina T, Tsuda M, Tsumura T, Sugimoto N, Shimodaira H, Tokunaga S, Moriwaki T, Esaki T, Nagase M, Fujitani K, Yamaguchi K, Ura T, Hamamoto Y, Morita S, Okamoto I, Boku N, Hyodo I, J Clin Oncol 2012 30 Suppl 4002
20. A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma. Roy AC, Park SR, Cunningham D, Kang YK, Chao Y, Chen LT, Rees C, Lim HY, Tabernero J, Ramos FJ, Kujundzic M, Cardic MB, Yeh CG, de Gramont A, Ann Oncol 2013 24 1567 1573 10.1093/annonc/mdt002 23406728
21. Clinicopathological characteristics and treatment strategies in early gastric cancer: a retrospective cohort study. Ito H, Inoue H, Ikeda H, Onimaru M, Yoshida A, Hosoya T, Sudo K, Eleftheriadis N, Maselli R, Maeda C, Wada Y, Sando N, Hamatani S, Kudo SE, J Exp Clin Cancer Res 2011 30 117 10.1186/1756-9966-30-117 22206626
22. Clinicopathological characteristics and optimal management for esophagogastric junctional cancer; a single center retrospective cohort study. Ito H, Inoue H, Odaka N, Satodate H, Suzuki M, Mukai S, Takehara Y, Kida H, Kudo SE, J Exp Clin Cancer Res 2013 32 2 10.1186/1756-9966-32-2 23289488
23. Comparison of gastric cancer survival following R0 resection in the United States and Korea using an internationally validated nomogram. Strong VE, Song KY, Park CH, Jacks LM, Gonen M, Shah M, Coit DG, Brennan MF, Ann Surg 2010 251 640 646 10.1097/SLA.0b013e3181d3d29b 20224369
24. A microRNA expression signature of human solid tumors defines cancer gene targets. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, Croce CM, Proc Natl Acad Sci U S A 2006 103 2257 2261 10.1073/pnas.0510565103 16461460 (Pubitemid 43271657)
25. Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Ueda T, Volinia S, Okumura H, Shimizu M, Taccioli C, Rossi S, Alder H, Liu CG, Oue N, Yasui W, Yoshida K, Sasaki H, Nomura S, Seto Y, Kaminishi M, Calin GA, Croce CM, Lancet Oncol 2010 11 136 146 10.1016/S1470-2045(09)70343-2 20022810
26. Identifying molecular drivers of gastric cancer through next-generation sequencing. Liang H, Kim YH, Cancer Lett doi: 10.1016/j.canlet.2012.11.029. [Epub ahead of print]
27. Phase I pharmacokinetic study of S-1plus cisplatin in patients with advanced gastric carcinoma. Ajani JA, Faust J, Ikeda K, Yao JC, Anbe H, Carr KL, Houghton M, Urrea P, J Clin Oncol 2005 23 6957 6965 10.1200/JCO.2005.01.917 16145066
28. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advancedgastric or gastroesophageal adenocarcinoma study: the FLAGS trial. Ajani JA, Rodriguez W, Bodoky G, Moiseyenko V, Lichinitser M, Gorbunova V, Vynnychenko I, Garin A, Lang I, Falcon S, J Clin Oncol 2010 28 1547 1553 10.1200/JCO.2009.25.4706 20159816
29. Final results of the intergroup FFCDGERCOR-FNCLCC 03-07 phase III study comparing two sequences of chemotherapy in advanced gastric cancers [abstract ]. Guimbaud R, Louvet C, Bonnetain F, Viret F, Samalin E, Gornet JM, André T, Rebischung C, Bouche O, Jouve JL, Ann Oncol 2010 21 8 250
30. The efficacy and toxicity of irinotecan with leucovorin and bolus and continuous infusional 5-fluorouracil (FOLFIRI) as salvage therapy for patients with advanced gastric cancer previously treated with platinum and taxane-based chemotherapy regimens. Kaya AO, Coskun U, Gumus M, Dane F, Ozkan M, Iskdogan A, Alkis N, Buyukberber S, Yumuk F, Budakoglu B, Demirci U, Berk V, Bilici A, Inal A, Arpac E, Benekli M, Anatolian Society of Medical Oncology (ASMO), J Chemother 2012 4 217 220